CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies

This phase I trial studies the effects of CD-19 directed chimeric antigen receptor (CAR)-T cell therapy for the treatment of patients with B cell malignancies that have come back (recurrent) or have not responded to treatment (refractory). CD-19 CAR-T cells use some of a patient's own immune cells, called T cells, to kill cancer. T cells fight infections and, in some cases, can also kill cancer cells. Some T cells are removed from the blood, and then laboratory, researchers will put a new gene into the T cells. This gene allows the T cells to recognize and possibly treat cancer. The new modifi

Trial Details

NCT ID
NCT04892277
Phase
PHASE1
Sponsor
Mayo Clinic
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Autologous Anti-CD19 CAR-expressing T-lymphocytes IC19/1563
  • Bendamustine
  • Biospecimen Collection
  • Bone Marrow Aspiration
  • Bone Marrow Biopsy
  • Computed Tomography
Locations (sample)
  • Rochester, Minnesota, United States|44.02163,-92.4699

Key Eligibility Criteria

  • Age \>= 18 years
  • Relapsed or refractory CD19+ B cell malignancies of the one of the following histopathology:
  • Biopsy proven B-cell non-Hodgkin lymphoma (NHL) of any histopathology (including Richter Transformation of CLL); relapsed or refractory disease def…
  • Two or more prior lines of therapy, at least one anthracycline containing regimen, unless intolerable. Exception: Patients with Richter transformat…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →